China's first new crown mRNA vaccine has been approved to start clinical trials

outbreak of new crown pneumonia, the Institute of Military Medicine of the Academy of Military Sciences has deployed emergency scientific research and research, while promoting the development of new crown vaccines along several technical routes. The domestic new crown mRNA vaccine is another high-tech vaccine variety that has been successfully approved for clinical trials after recombining the new coronavirus vaccine (adenovirus vector). Studies have shown that this new coronary mRNA vaccine not only induces the production of high levels of neutral antibodies in mice and crab-eating monkeys, but also induces a protective T-cell immune response. Crab-eating monkeys have shown that vaccine-immune animals can withstand high-titration neo-coronavirus attacks, effectively prevent virus replication and lung pathological progression, and show good protective effects.
mRNA vaccine is a new form of vaccine in recent years, the basic principle is through a specific delivery system to express antigen target mRNA into the body, in the body to express proteins and stimulate the body to produce a specific immunological response, so that the body has immune protection. There is a high technical threshold for mRNA vaccine research and development, only a few mRNA vaccine varieties developed in the United States and Germany have entered the clinical research stage, China has never approved mRNA vaccine into clinical.